BIOTHERAPEUTICS DEVELOPABILITY
AND RISK MITIGATION

AGENDA

Check the program of the last edition HERE

DAY 1

Tuesday, 22 September 2026

08h00

Welcome Coffee & Registration

09h00

Welcome Address

- E-Lounge Auditorium

Chairman

10h00

Titre de la présentation

Logo Mabdesign

09h20

Opening Keynote Lecture

- E-Lounge Auditorium

Chairman

10h00

Digital Model for Enabling Process Monitoring and AI in Biologics Manufacturing

Guillaume JEANNE

Bioprocess Mechanistic Modeling & Advanced Process Control

Sanofi, France

10h00

International Panel - Understanding the Saudi Biopharma Ecosytem: Opportunities and Realities

- E-Lounge Auditorium

Chairman

10h00

Panelists

Dalal ALFARHAN

Investment Associate

Public Investment Fund (PIF), Kingdom of Saudi Arabia (KSA)

Mohammed JOBRAN

Regulatory Affairs Consultant & Founder

PharmaKnowl Consulting, KSA

Ahmed Saeed MOUSA

General Manager

Lafana Life Science, KSA

Junaid RAJA

Director of Operations

Lifera, KSA

10h30

Moderation

Prénom NOM

Fonction

Entreprise, Pays

11h10

Workshops

Chairman

12h10

Lunch Break at the Exhibition Hall - B2B Meetings

13h30

Innovations in Analytical Methods Supporting Biotherapeutic Development

- E-Lounge Auditorium

Chairman

10h00

Analytical and Functional Characterization of Next-Generation Therapeutics: ADCs, CAR T Cells, rAAVs, mRNA and VLPs

Alain BECK

Senior Director Biologics CMC and Developability

Pierre Fabre Laboratories, France

10h00

Characterizing ADCs and Complex Biologics: New Insights

Dan Bach KRISTENSEN

Scientific Director

Servier Symphogen, Denmark

10h00

A New Shared Robotic Platform Advancing Analytical Sciences

Lilian RIPOLL

Scientific Coordinator

Sanofi, France

10h00

Titre de la présentation

10h00

Titre de la présentation

Prénom NOM

Fonction

SciY, United Kingdom

10h00

Titre de la présentation

Prénom NOM

Fonction

PathoQuest, France

10h00

Titre de la présentation

Prénom NOM

Fonction

Repligen, France

Next-Generation Biotherapies: Bridging Innovation, Manufacturability and Developability

- H-Experience Auditorium

Chairman

10h00

Developability Across Antibody Modalities

Anne-Laure LAINE

Director Preclinical Development

Ridgeline Discovery, Switzerland

10h00

Advancing Bispecific and Multispecific Antibodies

Cyrille DREYFUS

Associate Director & Head of Protein Sciences

Ichnos Sciences, France

10h00

Automated Upstream Monitoring for Enhanced Bioprocess Performance

Charles HEBERT

CEO & Executive Board Member

GenSensor, France

10h00

Upstream and Downstream Processes Intensification as a Lever for Innovative and Competitive Antibody Manufacturing

David BALBUENA

Director of Business Development

LFB Biomanufacturing, France

10h00

Chemical Synthesis Tools for Biotherapeutics

Reda MHIDIA

CEO & Co-Founder

CliniScience, France

10h00

Titre de la présentation

Prénom NOM

Fonction

Hamilton, Switzerland

10h00

Titre de la présentation

Prénom NOM

Fonction

Chime Biologics, Switzerland

15h15

Coffee Break at the Exhibition Hall - B2B Meetings

16h00

Breakthrough Innovations in Bioprocessing

- E-Lounge Auditorium

Chairman

A Call for Abstracts is open until July 3, 2026. Selected presentations will be announced by the end of July.

10h00

Titre de la présentation

Logo Mabdesign

Prénom NOM

Fonction

Entreprise, Pays

Formulation & Stability challenges During Clinical Development

- H-Experience Auditorium

Chairman

10h00

In-Use Stability of Antibody-Drug Conjugates

Sandrine FLEURY-SOUVERAIN

Quality Control Laboratory Manager

Hôpitaux universitaires de Genève, Switzerland

10h00

Clinical In-Use Approaches for mAbs and Biosimilar Analysis

Emmanuel DOUEZ

Pharm. D.

University of Tours, France

10h00

Title

Sandrine FLEURY-SOUVERAIN

Quality Control Laboratory Manager

University of Geneva, Switzerland

10h00

Title

Sandrine FLEURY-SOUVERAIN

Quality Control Laboratory Manager

University of Geneva, Switzerland

17h00

Round Table - Canadian Delegation

- E-Lounge Auditorium

Chairman

Supported by the Embassy of Canada in France, this panel discussion will highlight the strengths of the Canadian biopharmaceutical ecosystem and explore opportunities for collaboration with European stakeholders.

10h00

Titre de la présentation

Prénom NOM

Fonction

Entreprise, Pays

18h00

Biotuesdays

- E-Lounge Auditorium

Chairman

The BioTuesday is a flagship life sciences and healthcare networking event organized by the Lyon Metropolitan Area. This special session will showcase the expertise and innovations of leading academic, clinical and industrial organizations from the Auvergne-Rhône-Alpes region, fostering exchanges and collaboration opportunities with an international audience.

10h00

Titre de la présentation

19h00

Poster Session at the Exhibition Hall - Wine & Cheese

21h00

End of Day 1

Fabien Compeau

Design and development of chemically defined media supplemented with vegetable protein hydrolysates to enhance CHO cell growth and monoclonal antibody production

Abstract

In the realm of biopharmaceutical production, Chinese Hamster Ovary (CHO) cells have emerged as the main expression system for recombinant therapeutic proteins (RTPs), despite the availability of several alternative cell lines. CHO cells are among the most widely used worldwide for their unique advantages, e.g, the variety of post-translational modifications that closely mimic those found on human cells (Stach et al. 2019); their high degree of biosafety due to their low risk of propagation of human viruses infection (Lalonde and Durocher, 2017); their adaptability from adherent to suspension cell culture in serum-free media (Davami et al. 2014). Thanks to these combined attributes that solidified the position of CHO cells, they have become the gold-standard of the bioindustry and are responsible for the production of approximately 70% of all marketed RTPs (Pereira et al., 2018; Stolfa et al., 2018; Dziomba et al. 2023).

 

Fetal bovine serum (FBS) is commonly used as a supplement to basal media for in vitro cell cultures (including mammalian, animal, insect, and bacterial cells). Many studies have revealed its rich composition, containing essential macro- and micronutrients such as growth factors, adherent factors, amino acids, hormones, and vitamins (Michael Butler et al. 2020), which are crucial for proper cell function. In addition to the ethical issue, increasing demand, high cost, significant contamination risks (bacterial and viral), and batch-to-batch variability of FBS prompt us to seek alternatives. To reduce or eliminate FBS use, we have decided to implement culture media with various plant protein hydrolysates. Although serum-free media have been available for several decades, and their widespread adoption has increased, despite the fact that their compositions are undefined for users. Our goal is to make these serum-free media more accessible considering that serum-free media cost about 1.5 to 3 times more than serum-containing media.

 

Several publications highlighted the effects of vegetable proteins hydrolysate (peptones) as supplements in basal media, i.e : the enhancing of the cell growth and productivity of recombinant proteins (Burteau et al. 2003; Michael J. Betenbaugh et al. 2020). Some publications have shown an enhancing of the volumetric productivity more than 100%, and a 40% increase in cell number (Davami et al. 2014; Davami et al. 2015). Then, the composition of these plant hydrolysates varies according to the plant source and the production process. Thanks to their vegetable origins there are neither ethical issues, nor health standards.

 

In the present study, the effect of different peptone concentrations on the CHO-K1 cell line under various culture conditions (adherent/suspension) in a basal medium with a 10-fold reduction of FBS have been evaluated. Supplementation with wheat peptones at defined concentrations increased the viable cell density of CHO-K1 in adherent conditions by 190 – 265%.

 

Additionally, the suspension culture exhibited different results compared to the adherent conditions. In suspension cell culture, only three peptones – wheat, soy, and pea – enhanced viable cell density compared to the medium without hydrolysates. Actually, the only peptone supplementation is not enough to be completely serum-free, but that can reduce the FBS consumption.

Biography

Fabien Compeau is a researcher at both Organotechnie and Université Sorbonne Paris Nord, within the Tissue Engineering Research Unit. With a solid foundation in molecular and cellular biology. His current work centers on developing serum-free media. He completed three years of study at CY Cergy Paris Université and two years at Université Paris Cité. His internships provided valuable experience at the Institut de Recherche Criminelle de la Gendarmerie Nationale, the Institut Jacques Monod, and the Institut Pasteur, his research
focused on cell signaling, dynamics, and differentiation.

Igor Chourpa

Molecular optical spectroscopy as a PAT tool in USP bioprocessing

Abstract

Process analytical technology (PAT) aims at real-time, sampling-free monitoring of bioprocesses, for instance at the upstream stage (USP), when suspensions of CHO (chinese hamster ovary) cells grow in bioreactors and produce monoclonal antibodies (mAbs). The advantages of in-line PAT over the off-line approaches are numerous, from scientific, economic and ecological points of view. Using light as a non-invasive PAT tool is one of the promising ideas that give rise to various technological solutions. Nevertheless, the implementation of novel PAT approaches is limited and still requires further progress in analytical instrumentation and its integration in the whole process.
In this talk, we plan to present a short overview of advances in implementation of molecular optical spectroscopy as a PAT tool in upstream processing of therapeutic antibodies we obtained in the framework of our interdisciplinary research project CLIMB’IN. The project uses analytical spectroscopy based on light absorption and/or multi-angle scattering, both elastic (Rayleigh) and inelastic (Raman) for quantitative monitoring of multiple critical process parameters (CPPs). The advances reached by the CLIMB’IN consortium involve instrumental design and experimental protocols, with a particular focus made on machine learning algorithms. Brought together, these advances allow to improve the relevance and the robustness of the corresponding PAT approaches required for their industrial implementation.

Anne-Sophie GARY

Innovative tools to monitor biological variability of bioprocesses

Abstract

Today, virus-based products like oncolytic viruses and gene therapies are part of the most promising biotherapies. The development of biomanufacturing processes for viral products is not a straight road. It is generally associated with process complexity and biological variability. In depth expression system characterization by adding biological data to standard chemical data will help to understand bioprocesses. With a close collaboration between Naobios and Gensensor, case study from Vero cell substrate-based process will illustrate how transcriptomic data may help to understand and monitor biological variability linked to bioprocesses.

Biography

Anne-Sophie has a PhD in cell biology and is engineer in biotechnology. After working on cell stress and death pathways, Anne-Sophie specialized in the development of advanced therapy medicinal product. Now Principal Scientist at GenSensor, she is in charge of identifying biomarker panels on different expression systems and leads, with her team, the company’s internal research projects and scientific collaborations.